Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

115.33 +2.56 (+2.27%)
Streaming Delayed Price Updated: 11:42 AM EDT, Sep 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
64 65 Next >
Gilead Sciences Tops Q3 Earnings And Revenue Estimates
While Gilead has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? 
Via Talk Markets
Gilead Sciences (GILD) Q3 2023 Earnings Call Transcript
GILD earnings call for the period ending September 30, 2023. 
Via The Motley Fool
Topics Earnings
Gilead Sciences Stock Slides After Hours On Q3 Report - Here's Why
Gilead Sciences, Inc. (NASDAQ: GILD) shares are volatile in Tuesday's after-hours session on the heels of the company's  
Via Benzinga
Gilead Sciences Announces Third Quarter 2023 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
Gilead Squashes Expectations On The Back Of A Bullish Move For Its Cancer Drugs
The biotech company makes three notable treatments for cancer. 
Via Investor's Business Daily
If You Invested $100 In This Stock 20 Years Ago, You Would Have $1,200 Today
 
Via Benzinga
This Is What Whales Are Betting On Gilead Sciences
 
Via Benzinga
Comparative Study: Gilead Sciences And Industry Competitors In Biotechnology Industry
 
Via Benzinga
Positive News For Gastric Cancers - Gilead/Arcus Biosciences' Combination Cancer Therapy Shows Encouraging Clinical Activity
Gilead Sciences Inc (NASDAQ: GILD) and Arcus Biosciences Inc (NYSE: RCUS) announced that domvanalimab plus zimberelimab and chemotherapy showed encouraging overall response rate (ORR) and six-month... 
Via Benzinga
S&P 500, Nasdaq Set To Break 6-Day Rally Today? Traders Await Fed Cues, Analyst Says Seasonal Rally Has Started With Gusto
Sentiment appears to have dipped after a six-session winning streak. Stock futures indicate a modestly lower opening on Tuesday as small and mid-cap earnings reports gain momentum. 
Via Benzinga
Topics Economy Stocks
Gilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-line Treatment for Upper GI Cancers
From Gilead Sciences, Inc.
Via Business Wire
Fed Holds Rates Steady, Powell's Cautious Stance Soothes Investors, Labor Market Softens: The Week In The Markets
Markets bounced back decisively this week, shrugging off prior volatile months marked by heightened geopolitical tensions. The resurgence of risk sentiment ignited a relief rally in both equities and... 
Via Benzinga
Topics Bonds Economy
Gilead to Present Late Breaking Data and Real World Evidence Highlighting Key Hepatitis Indications at The Liver Meeting® 2023
From Gilead Sciences, Inc.
Via Business Wire
Gilead and Kite Oncology Present Data Demonstrating Car T-cell Therapy Survival Benefit and Showcasing Latest Advances in Blood Cancer Portfolio at ASH 2023
From Gilead Sciences, Inc.
Via Business Wire
Leidos Sees Robust Demand In Digital Modernization, Raises Annual Outlook
Leidos Holdings, Inc (NYSE: LDOS) reported third-quarter FY23 revenue growth of 9% year-over-year to $3.92 billion, beating the consensus of $3.77 billion.  
Via Benzinga
Kite and Epic Bio Announce Collaboration to Develop New Therapies for Cancer
From Gilead Sciences, Inc.
Via Business Wire
3 Pharma Stocks That Are Screaming Buys in October
Each company delivers an above-average dividend and revenue growth. 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Gilead Named Number One Overall Philanthropic Funder of HIV-Related Programs for Second Year in a Row by Funders Concerned About AIDS
From Gilead Sciences, Inc.
Via Business Wire
7 Healthcare Stocks to invest in for a Healthy Future
Considering today's economic uncertainty and market turns, healthcare stocks may be one of the few winning sectors. Here are the winners. 
Via InvestorPlace
New Data Presented at EACS 2023 Further Demonstrate Strong Clinical Profile of Twice-Yearly Sunlenca® for Adults With Multi-Drug Resistant HIV
From Gilead Sciences, Inc.
Via Business Wire
Pfizer Decides To Raise COVID-19 Treatment Pill Price, Defends Itself Amid Criticism for Cost Increase
Pfizer Inc (NYSE: PFE) is reportedly gearing up to price its Covid-19 drug Paxlovid at $1,390 for a five-day course, more than double what the U.S. government initially paid for it, at $529.  
Via Benzinga
Vertex Pharmaceuticals, Gilead Sciences And 2 Other Stocks Insiders Are Selling
The Nasdaq 100 closed lower by over 200 points on Wednesday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
Real-World Evidence Reinforces Biktarvy® as a Long-Term Treatment Option With a High Barrier to Resistance for People With HIV and a Range of Comorbidities
From Gilead Sciences, Inc.
Via Business Wire
Why AstraZeneca's Disappointing Lung Cancer Update Also Tripped Gilead Stock
The companies are hoping to use antibody drug conjugates in lung cancer patients. 
Via Investor's Business Daily
Gilead Sciences Announces New Clinical Trial in Europe to Assess Lenacapavir for HIV Prevention as Part of Landmark Purpose Program
From Gilead Sciences, Inc.
Via Business Wire
Why Is Assembly Biosciences (ASMB) Stock Up 92% Today?
Assembly Biosciences stock is taking off with heavy trading of ASMB shares after the company announced a new collaboration agreement! 
Via InvestorPlace
Hepatitis-Focused Assembly Biosciences Stock Trading Over 100% Higher: Here's Why
Gilead Sciences Inc (NASDAQ: GILD) and Assembly Biosciences Inc (NASDAQ: ASMB) have entered into a 12-year partnership. 
Via Benzinga
Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases
From Gilead Sciences, Inc.
Via Business Wire
Gilead and Kite Oncology Present Important New Data Across Multiple Difficult-to-Treat Cancers at ESMO Congress 2023
From Gilead Sciences, Inc.
Via Business Wire
< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
64 65 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.